James J Vredenburgh
Overview
Explore the profile of James J Vredenburgh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
5534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mar N, Desjardins A, Vredenburgh J
Clin Cancer Res
. 2015 Oct;
21(19):4248-50.
PMID: 26429979
Vredenburgh and colleagues conducted the first phase II study of bevacizumab plus irinotecan in recurrent malignant glioma, confirming the safety and efficacy of bevacizumab. This study, which was published in...
12.
Peters K, Lou E, Desjardins A, Reardon D, Lipp E, Miller E, et al.
Oncologist
. 2015 May;
20(7):727-8.
PMID: 26025933
Lessons Learned: Trials focusing on unresectable multifocal glioblastoma are needed because of the extremely poor prognosis and challenges in receiving standard therapy, such as concurrent radiation and chemotherapy.Developing a strategy...
13.
Mitchell D, Batich K, Gunn M, Huang M, Sanchez-Perez L, Nair S, et al.
Nature
. 2015 Mar;
519(7543):366-9.
PMID: 25762141
After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and...
14.
Mar N, Vredenburgh J, Wasser J
Lung Cancer
. 2015 Jan;
87(3):220-5.
PMID: 25601485
Oncogenic driver mutations have emerged as major treatment targets for molecular therapies in a variety of cancers. HER2 positivity has been well-studied in breast cancer, but its importance is still...
15.
Mar N, Gorgan M, Dailey M, Vredenburgh J
Am J Hematol
. 2013 Aug;
88(12):1090-3.
PMID: 23918652
No abstract available.
16.
Cabrera A, Cuneo K, Desjardins A, Sampson J, McSherry F, Herndon 2nd J, et al.
Int J Radiat Oncol Biol Phys
. 2013 Jun;
86(5):873-9.
PMID: 23725997
Purpose: Virtually all patients with malignant glioma (MG) eventually recur. This study evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ), an antiangiogenic agent, in treatment of recurrent...
17.
Jiang X, Reardon D, Desjardins A, Vredenburgh J, Quinn J, Austin A, et al.
J Neurooncol
. 2013 May;
114(1):135-40.
PMID: 23686298
Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL). The enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) repairs alkylating damage, such as that induced by temozolomide. We...
18.
Lou E, Peters K, Sumrall A, Desjardins A, Reardon D, Lipp E, et al.
Cancer Med
. 2013 May;
2(2):185-95.
PMID: 23634286
Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6-10 months. We conducted a phase II trial of upfront 5-day temozolomide (TMZ) and bevacizumab (BV) in patients...
19.
Cabrera A, Cuneo K, Vredenburgh J, Sampson J, Kirkpatrick J
J Natl Compr Canc Netw
. 2012 Jun;
10(6):695-9.
PMID: 22679114
Despite contemporary surgery, image-guided radiotherapy, and chemotherapy, glioblastoma multiforme (GBM) persists or relapses in nearly all patients, and tumors almost always recur locally. Management of recurrent GBM is variable, but...
20.
Lou E, Sumrall A, Turner S, Peters K, Desjardins A, Vredenburgh J, et al.
J Neurooncol
. 2012 Apr;
109(1):63-70.
PMID: 22535433
Intracranial meningiomas are often indolent tumors which typically grow over years to decades. Nonetheless, meningiomas that progress after maximum safe resection and radiation therapy pose a significant therapeutic challenge and...